Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double‐blind (BLESS) study
Article in Psychiatry and Clinical Neurosciences (December 2023)